Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Leukemia entities : Gilead sciences, inc. save search
Global Acute Lymphoblastic Leukemia Therapeutics Market Research 2024-2033: Developments Review, Regulatory Landscape, Competitive Benchmarking, Dynamic Landscape
Published: 2024-03-29 (Crawled : 18:00) - prnewswire.com
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
| Email alert
Add to watchlist
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
AMGN | News | $271.98 1.13% 1.12% 2.1M
|
Health Technology
| Email alert
Add to watchlist
GMAB | News | $28.97 0.94% 0.93% 450K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $95.12 0.81% -1.18% 2.4M
|
Health Technology
| Email alert
Add to watchlist
GNMSF | News | $284.55 3.83% 240
|
Health Technology
| Email alert
Add to watchlist
ABBV | News | $167.89 0.89% 0.0% 5.6M
|
Health Technology
| Email alert
Add to watchlist
research global leukemia therapeutics market
Global Neutropenia Market to Reach $5.77 Billion by 2028 with a CAGR of 6.2%: Growing Prevalence of Leukemia Drives Demand
Published: 2023-08-29 (Crawled : 17:00) - prnewswire.com
BAX | $40.4 2.36% 0.0% 3.2M
|
Health Technology
|
| O: 0.48%
H: 1.4%
C: 1.15%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 0.34%
H: 0.0%
C: 0.0%
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: 0.27%
H: 1.29%
C: 1.24%
BIIB | $194.1 -0.14% -0.15% 1.1M
|
Health Technology
|
| O: 0.11%
H: 1.06%
C: 1.0%
reach global growing leukemia market
Kite’s Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Published: 2023-02-09 (Crawled : 13:00) - biospace.com/
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: 0.19%
H: 0.9%
C: -0.35%
tecartus t-cell leukemia trial therapy
ImmunoGen Announces Clinical Collaboration with Gilead to Evaluate Pivekimab Sunirine in Combination with Magrolimab in Relapsed/Refractory Acute Myeloid Leukemia
Published: 2022-12-09 (Crawled : 13:00) - biospace.com/
IMGN | News | $31.23 0.03% 49M
|
Health Technology
|
| O: -0.19%
H: 0.77%
C: -0.77%
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -1.45%
collaboration leukemia acute myeloid leukemia
Kronos Bio Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Lanraplenib in Combination with Gilteritinib in Acute Myeloid Leukemia
Published: 2022-08-22 (Crawled : 13:00) - biospace.com/
KRON | $0.9714 -3.82% -3.97% 170K
|
Health Technology
|
| O: -1.64%
H: 1.19%
C: -4.53%
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: -0.2%
H: 0.06%
C: -1.3%
leukemia trial acute myeloid leukemia phase 2b
Kite’s CAR T-cell Therapy Tecartus® Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)
Published: 2022-07-22 (Crawled : 15:00) - biospace.com/
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: 0.43%
H: 0.86%
C: -0.77%
tecartus chmp t-cell leukemia positive therapy
GM-CSF Knock-out CAR-T Study Published in Peer-Reviewed Journal Leukemia
Published: 2022-04-20 (Crawled : 13:20) - biospace.com/
HGEN | $0.0361 -61.5% 120M
|
Health Technology
|
| O: 3.49%
H: 1.48%
C: -5.06%
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: 2.4%
H: 0.0%
C: 0.0%
car-t leukemia
U.S. FDA Approves Kite’s Tecartus® as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Published: 2021-10-01 (Crawled : 00:20) - biospace.com/
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: -1.29%
H: 0.0%
C: 0.0%
fda leukemia fda approval car-t t-cell
Kite's Tecartus® Demonstrates High Response Rate in Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Earning Priority Review Designation
Published: 2021-06-04 (Crawled : 20:00) - biospace.com/
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: 0.47%
H: 1.17%
C: 0.96%
leukemia t-cell designation
Global Acute Lymphoblastic Leukemia Treatment Market Research Report (2020 to 2025) - by Types of Cell, Therapy and Region
Published: 2021-03-24 (Crawled : 17:00) - prnewswire.com
TAK | News | $13.36 0.91% -0.52% 1.6M
|
Health Technology
|
| O: -0.36%
H: 0.36%
C: -0.21%
GSK | News | $40.59 2.11% -0.36% 3.8M
|
Health Technology
|
| O: -0.86%
H: 1.01%
C: 0.53%
SPPI | $1.03 -0.97% 0
|
Health Technology
|
| O: 0.95%
H: 0.91%
C: -9.38%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -0.25%
H: 0.39%
C: 0.27%
JAZZ | $108.81 -1.03% -1.04% 510K
|
Health Technology
|
| O: 0.54%
H: 1.24%
C: -0.9%
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: -0.22%
H: 1.09%
C: -0.02%
GMAB | News | $28.97 0.94% 0.93% 450K
|
Health Technology
|
| O: -0.76%
H: 0.0%
C: -2.59%
TECH | $62.79 1.08% 1.07% 830K
|
Health Technology
|
| O: 0.32%
H: 1.09%
C: -2.18%
treatment therapy leukemia research
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.